ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• A Glass Package Designed Specifically for Pharmaceutical Use

  A comprehensive solution for multiple glass quality issues that affect drug products is essential to avoid costly delays and drug product recalls, all while increasing patient safety.

• Formulation Considerations For Pediatric Populations

  By partnering with a CDMO with experience in pediatric formulation, pharmaceutical companies can increase acceptability of their drugs among pediatric patients.

• Overcoming A Failed Design Verification Test For Your Delivery Device

  If a drug delivery device fails a design verification test, the consequences can be lost revenue for the pharma company and delays for patients. Explore how to eliminate design verification failure.

• Steps To Overcome Challenges Associated With Biologic Formulation Development

  Explore guidance on the challenges posed by biologics, including overcoming degradation, establishing a stress test process, and the value of lipid nanoparticles (LNPs) and polymeric nanoparticles (NPs).

• FAQs On The Revised EU GMP Annex 1: Volume 3

  The EU GMP Annex 1 revision, effective August 2023, requires a detailed Contamination Control Strategy. Learn how it impacts global manufacturers, RABS use, and personnel procedures.

• Key Considerations When Choosing A Device For Dry Powder Nasal Delivery

  Building on previous discussions, here we discuss the benefits of nasal delivery and the challenges of developing dry powder formulations by focusing on key devices that can be used for delivering dry powder nasal dosage forms.

• An Easy-To-Swallow Depression Drug For Elderly Patients

  Examine how an innovative formulation approach helped a developer create a version of their drug that promotes treatment compliance within the geriatric population.

• Viral Vector Based Gene Therapy Drug Products: The Right Primary Container

  Explore the major considerations for an ideal primary container for viral vector-based gene therapy drug products and the existing and new solutions in this space.

• Expanding Home-Based Care With A Next-Gen On-Body Delivery System

  As on-body delivery systems (OBDSs) enable the shift to patient-centric treatment, manufacturers must optimize the device and therapy formulation to minimize the risks and increase adherence.

• Combining Patient Centricity And Commercial Viability In Pediatric Product Development

  Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development.